Insight Molecular DiagnosticsIMDX -3.80%49 Net Debt Paydown Yield % is 0.23% as of Jul. 01, 2026, which is 8% below its 10-year median of 0.25. GuruFocus rates IMDX with a GF Score™ of 49/100 and a GF Value™ of $1.25 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 199 Medical Diagnostics & Research companies, Insight Molecular Diagnostics ranks better than 58.29% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, Insight Molecular Diagnostics's Net Debt Paydown Yield % was 0.23%.
Insight Molecular Diagnostics (NAS:IMDX) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insight Molecular Diagnostics Net Debt Paydown Yield % Chart
IMDX vs XGN, BDSX, BNR: Net Debt Paydown Yield % Comparison
For the Diagnostics & Research subindustry, Insight Molecular Diagnostics's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insight Molecular Diagnostics Net Debt Paydown Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Insight Molecular Diagnostics's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where Insight Molecular Diagnostics's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of 0.23% mean?
Insight Molecular Diagnostics (IMDX) has a Net Debt Paydown Yield % of 0.23% as of Jul. 01, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Insight Molecular Diagnostics and its competitors. This is near median its historical median of 0.25. According to the industry distribution chart, Insight Molecular Diagnostics ranks #83 out of 199 companies in the Medical Diagnostics & Research industry, placing it in the top 41.7%.
Is Insight Molecular Diagnostics' Net Debt Paydown Yield % too high?
Insight Molecular Diagnostics' current Net Debt Paydown Yield % of 0.23% is near median its 10-year median of 0.25. Based on the distribution chart, Insight Molecular Diagnostics ranks #83 out of 199 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Insight Molecular Diagnostics has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Insight Molecular Diagnostics' Net Debt Paydown Yield % compare to XGN and BDSX?
According to the Medical Diagnostics & Research industry distribution chart, Insight Molecular Diagnostics ranks #83 out of 199 companies for Net Debt Paydown Yield %. This puts Insight Molecular Diagnostics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Medical Diagnostics & Research company?
A good Net Debt Paydown Yield % depends on the Medical Diagnostics & Research industry context. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Insight Molecular Diagnostics and its competitors. Insight Molecular Diagnostics's current Net Debt Paydown Yield % is 0.23%, which is near median its own 10-year median of 0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insight Molecular Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Insight Molecular Diagnostics (IMDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.25, compared to a current price of $5.69 — trading 355.2% above its estimated fair value. The current Net Debt Paydown Yield % is 0.23%, which is near median its 10-year median of 0.25. Insight Molecular Diagnostics' overall GF Score™ is 49/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For Insight Molecular Diagnostics (IMDX), the current Net Debt Paydown Yield % is 0.23% as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Insight Molecular Diagnostics (IMDX) Overvalued in 2026?
Based on GuruFocus' analysis, Insight Molecular Diagnostics stock appears to be overvalued.
The current stock price of $5.69 is trading 355.2% above its estimated GF Value™ of $1.25.
GuruFocus considers Insight Molecular Diagnostics to be Significantly Overvalued.
Key valuation signals for IMDX:
Net Debt Paydown Yield %: 0.23% (near median its 10-year median of 0.25)
GF Value™: $1.25 vs. price of $5.69 (355.2% above fair value)
No single metric tells the full story. See the IMDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Insight Molecular Diagnostics Business Description
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
49GF Score
Get the complete analysis for IMDX
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMDX has been successfully added to your 
